newsfilter
← Latest News
Business Wire·

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

Highlights Early Efficacy of CytRx's Licensed Drug Aldoxorubicin in ImmunityBio's Phase 2 Trial of Nant Cancer Vaccine for Third Line or Greater Pancreatic Cancer Patients Notes 90% of All Evaluable Patients and 87% of Patients With Extremely Advance